1.76
+0.03(+1.73%)
Currency In USD
| Previous Close | 1.73 |
| Open | 1.74 |
| Day High | 1.84 |
| Day Low | 1.7 |
| 52-Week High | 3.75 |
| 52-Week Low | 1.43 |
| Volume | 8,270 |
| Average Volume | 15,337 |
| Market Cap | 70.93M |
| PE | -4.4 |
| EPS | -0.4 |
| Moving Average 50 Days | 1.71 |
| Moving Average 200 Days | 2.01 |
| Change | 0.03 |
If you invested $1000 in BeyondSpring Inc. (BYSI) since IPO date, it would be worth $104.76 as of March 14, 2025 at a share price of $1.76. Whereas If you bought $1000 worth of BeyondSpring Inc. (BYSI) shares 5 years ago, it would be worth $181.82 as of March 14, 2025 at a share price of $1.76.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
GlobeNewswire Inc.
Jan 28, 2025 12:00 PM GMT
FLORHAM PARK, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has entered
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
GlobeNewswire Inc.
Nov 11, 2024 1:00 PM GMT
In 30 metastatic NSCLC patients who progressed on PD-1/PD-L1 inhibitors, the triple IO combo regimen at median follow-up time of 11.5 months achieved a DCR of 89.3% and Median PFS of 8.6 monthsFLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- B
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
GlobeNewswire Inc.
Sep 16, 2024 11:00 AM GMT
Plinabulin/Docetaxel Combination Demonstrated Favorable Benefit/Risk Ratio over Docetaxel Alone: Significant Improvement in Overall Survival, Progression Free Survival, and Objective Response, with additional Significant Reduction of Grade 4 Neutrope